The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response

Gut

Volumn 59, Issue 8, 2010, Pages 1111-1119

  Broering, Ruth ^a   Zhang, Xiaozhen ^b   Kottilil, Shyam ^b   Trippler, Martin ^a   Jiang, Min ^a   Lu, Mengji ^a   Gerken, Guido ^a   Schlaak, Joerg F ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON STIMULATED GENE 15; NONSTRUCTURAL PROTEIN 5A; NUCLEIC ACID BINDING PROTEIN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; CYTOKINES; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; LIVER NEOPLASMS; MICE; PROTEASE INHIBITORS; REPLICON; RIBAVIRIN; RNA, SMALL INTERFERING; UBIQUITINS; VIRAL LOAD; VIRUS REPLICATION;

EID: 77954726570     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.195545     Document Type: Article

References (39)

1. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
3. McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003;7:149-61.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
5. Bigger CB, Guerra B, Brasky KM, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004;78:13779-92. (Pubitemid 39612775)
6. Foy E, Li K, Sumpter R Jr, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 2005;102:2986-91.
7. Sumpter R Jr, Loo YM, Foy E, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005;79:2689-99. (Pubitemid 40270547)
8. Helbig KJ, Lau DT, Semendric L, et al. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 2005;42:702-10. (Pubitemid 41233665)
9. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005;102:2992-7.
10. Broering R, Wu J, Meng Z, et al. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008;48:914-22.
11. Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008;57:516-24.
12. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-44.
13. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001;55:255-81.
14. Malakhov MP, Malakhova OA, Kim KI, et al. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 2002;277:9976-81.
15. Ritchie KJ, Zhang DE. ISG15: the immunological kin of ubiquitin. Semin Cell Dev Biol 2004;15:237-46.
16. Lenschow DJ, Lai C, Frias-Staheli N, et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A 2007;104:1371-6.
17. Girard S, Shalhoub P, Lescure P, et al. An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology 2002;295:272-83. (Pubitemid 34921313)
18. Naganuma A, Nozaki A, Tanaka T, et al. Activation of the interferon-inducible 29-59-oligoadenylate synthetase gene by hepatitis C virus core protein. J Virol 2000;74:8744-50.
19. Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001;75:8516-23. (Pubitemid 32768956)
20. Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-13. (Pubitemid 29307577)
21. Zhu Q, Guo JT, Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 2003;77:9204-10. (Pubitemid 37011017)
22. Denzer U, Helmreich-Becker I, Galle PR, et al. Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding. Am J Gastroenterol 2003;98:893-900. (Pubitemid 36576320)
23. Asselah T, Bieche I, Laurendeau I, et al. Significant gene expression differences in histologically "normal" liver biopsies: implications for control tissue. Hepatology 2008;48:953-62.
24. Rakesh K, Agrawal DK. Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol 2005;70:649-57. (Pubitemid 41058699)
25. Hilkens CM, Schlaak JF, Kerr IM. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J Immunol 2003;171:5255-63.
26. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-6.
27. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-6.
28. Zhao C, Denison C, Huibregtse JM, et al. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci U S A 2005;102:10200-5. (Pubitemid 41023349)
29. Chua PK, McCown MF, Rajyaguru S, et al. Modulation of the interferon {alpha} anti-hepatitis C virus activity by ISG15. J Gen Virol 2009;90:2929-39.
30. Randall G, Panis M, Cooper JD, et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 2007;104:12884-9.
31. Kunzi MS, Pitha PM. Role of interferon-stimulated gene ISG-15 in the interferon-omega-mediated inhibition of human immunodeficiency virus replication. J Interferon Cytokine Res 1996;16:919-27.
32. Yuan W, Krug RM. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J 2001;20:362-71. (Pubitemid 32126972)
33. Lenschow DJ, Giannakopoulos NV, Gunn LJ, et al. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol 2005;79:13974-83.
34. Kim KI, Yan M, Malakhova O, et al. Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol 2006;26:472-9. (Pubitemid 43089760)
35. Osiak A, Utermohlen O, Niendorf S, et al. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol Cell Biol 2005;25:6338-45. (Pubitemid 41023211)
36. Kim JH, Luo JK, Zhang DE. The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression. J Immunol 2008;181:6467-72.
37. Malakhova OA, Kim KI, Luo JK, et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006;25:2358-67.
38. Randall G, Chen L, Panis M, et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006;131:1584-91.
39. Asselah T, Bieche I, Sabbagh A, et al. Gene expression and hepatitis C virus infection. Gut 2009;58:846-58.